Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Entergy Corporation (ETR) vs Mesoblast Limited (MESO) Price & Performance

Entergy CorporationTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Entergy Corporation vs Mesoblast Limited — how do they compare? Entergy Corporation trades at $102.77 (market cap $49.12B), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: Entergy Corporation is far larger — about 28.1× Mesoblast Limited's market cap, and Entergy Corporation pays a 2.49% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entergy Corporation for 9 Days and Mesoblast Limited for 15 Days on average.

ETRMESO
Market Cap
$49.12B$1.75B
Volume
2,228,388239,027
Sector
UtilitiesHealth
52-Week High
$117.91$20.96
52-Week Low
$91.19$13.19
Typical Hold Time
9 Days15 Days
Enterprise Value
$79.89B$1.83B
Dividend Yield
2.49%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Entergy Corporation

No Aura AI signal available yet.

Mesoblast Limited

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Entergy Corporation

Entergy is an energy company that operates regulated electric utilities and power generation businesses in the United States. Its generation portfolio includes nuclear, natural gas, and renewable resources.

Read more on ETR →

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO →